Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Protective immunity in hamsters from an oral Nipah vaccine correlates with pseudovirus neutralising antibody titre.

Scientific reports·2026

Same author

Dissecting biomarker networks linking COVID-19 inflammatory drivers, disease severity and thyroid adaptive responses.

Scientific reports·2025

Same author

Corrigendum to "Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome" [Journal of Molecular and Cellular Cardiology 138 (2020) 291-303].

Journal of molecular and cellular cardiology·2025

Same author

Thyroid function during COVID-19 and post-COVID complications in adults: a systematic review.

Frontiers in endocrinology·2025

Same author

PIEZO1 overexpression in hereditary hemorrhagic telangiectasia arteriovenous malformations.

bioRxiv : the preprint server for biology·2024

Same author

LDL receptor-related protein 5 selectively transports unesterified polyunsaturated fatty acids to intracellular compartments.

Nature communications·2024

Search research articles

Related Experiment Video

Updated: Jun 9, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Progress toward an Epstein-Barr virus vaccine.

Craig Laferriere¹, Elliot Bland¹, Wayne Channon¹

¹iosBio Ltd., Haywards Heath, UK.

Expert Review of Vaccines

|June 8, 2026

Summary

Epstein-Barr virus (EBV) is now recognized as the primary cause of multiple sclerosis (MS). Preventing EBV infection is crucial for eliminating most MS cases and reducing other diseases, accelerating vaccine development.

Keywords:

Epstein-Barr virus cancer clinical trials infectious mononucleosis multiple sclerosis vaccine

More Related Videos

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

Related Experiment Videos

Last Updated: Jun 9, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

Area of Science:

Virology
Immunology
Vaccinology

Background:

Epstein-Barr virus (EBV), or Human gammaherpesvirus 4, infects over 90% of the global adult population.
EBV establishes lifelong latency in B lymphocytes and is linked to various diseases, including infectious mononucleosis, cancers, and chronic inflammatory conditions.
A recent study identified EBV as the primary trigger for multiple sclerosis (MS).

Purpose of the Study:

To review the epidemiology of EBV-associated diseases.
To detail EBV biology, lifecycle, and potential vaccine target antigens.
To evaluate the immune response to natural infection and assess current vaccine candidates against established benchmarks.

Main Methods:

Epidemiological data analysis of EBV-associated cancers and inflammatory diseases.
Review of EBV virology, including its lifecycle and immune evasion strategies.
Assessment of prophylactic and therapeutic vaccine strategies, including target antigens and immune correlates of protection.

Main Results:

EBV is the leading cause of multiple sclerosis, necessitating preventative strategies.
Key viral antigens and immune responses relevant to vaccine development have been identified.
Existing vaccine candidates are evaluated against defined Target Product Profiles (TPPs).

Conclusions:

Preventing EBV infection is a critical strategy for eliminating the majority of MS cases worldwide.
The development of next-generation EBV vaccines is urgently needed and accelerated by recent discoveries.
Strategic collaboration and clear clinical endpoints are essential for the successful global implementation of an EBV vaccine.